Publication:
Any heart failure treatments associated with worsening renal function in patients admitted due to acute heart failure?

dc.contributor.authorLimkunakul C.
dc.contributor.authorSrisantithum B.
dc.contributor.authorLerdrattanasakulchai Y.
dc.contributor.authorLaksomya T.
dc.contributor.authorJungpanich J.
dc.contributor.authorSawanyawisuth K.
dc.date.accessioned2021-04-05T03:01:41Z
dc.date.available2021-04-05T03:01:41Z
dc.date.issued2021
dc.date.issuedBE2564
dc.description.abstractBackground: Worsening renal function (WRF) occurs in approximately 25% of acute heart failure patients, and both baseline characteristics and heart failure treatment may increase the risk of WRF. This study aimed to evaluate additional risk factors for WRF in acute heart failure, particularly those related to heart failure treatment. Methods: This was a retrospective, observational, analytical study. The inclusion criteria were age 18 years or over, hospital admission due to acute heart failure, and having undergone at least two serum creatinine tests during admission. The eligible patients were classified into two groups: WRF and non-WRF. Predictors for WRF (including treatment parameters) were determined using logistic regression analysis. Results: During the study period, there were 301 eligible patients who met the study criteria. Of those, 82 (27.24%) had WRF. There were two independent factors associated with WRF occurrence: baseline diastolic blood pressure and beta blocker treatment, with adjusted odds ratios (95% confidence interval) of 1.060 (1.008, 1.114) and 0.064 (0.006, 0.634), respectively. The Hosmer-Lemeshow Chi square for the final model was 6.11 (p =.634).   Conclusions: After examining several heart failure treatments and baseline factors, we found that beta blocker treatment results improvement in kidney function. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
dc.format.mimetypeapplication/pdf
dc.identifier.citationRenal Failure. Vol 43, No.1 (2021), p.123-127
dc.identifier.doi10.1080/0886022X.2020.1858100
dc.identifier.issn0886022X
dc.identifier.other2-s2.0-85099112324
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4743
dc.rightsSrinakharinwirot University
dc.rights.holderScopus
dc.subject.otherAngiotensin receptor antagonist
dc.subject.otherAntibiotic agent
dc.subject.otherBeta adrenergic receptor blocking agent
dc.subject.otherBrain natriuretic peptide
dc.subject.otherCalcium channel blocking agent
dc.subject.otherContrast medium
dc.subject.otherCreatinine
dc.subject.otherDipeptidyl carboxypeptidase inhibitor
dc.subject.otherFurosemide
dc.subject.otherGlyceryl trinitrate
dc.subject.otherHemoglobin
dc.subject.otherInotropic agent
dc.subject.otherNonsteroid antiinflammatory agent
dc.subject.otherSpironolactone
dc.subject.otherAcute heart failure
dc.subject.otherAged
dc.subject.otherArticle
dc.subject.otherChronic kidney failure
dc.subject.otherControlled study
dc.subject.otherCreatinine blood level
dc.subject.otherDiastolic blood pressure
dc.subject.otherDisease exacerbation
dc.subject.otherFemale
dc.subject.otherHeart ejection fraction
dc.subject.otherHeart rate
dc.subject.otherHospital admission
dc.subject.otherHuman
dc.subject.otherHuman tissue
dc.subject.otherKidney function
dc.subject.otherMajor clinical study
dc.subject.otherMale
dc.subject.otherObservational study
dc.subject.otherOxygen saturation
dc.subject.otherPriority journal
dc.subject.otherRetrospective study
dc.subject.otherRisk factor
dc.subject.otherSodium blood level
dc.subject.otherSystolic blood pressure
dc.titleAny heart failure treatments associated with worsening renal function in patients admitted due to acute heart failure?
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85099112324&doi=10.1080%2f0886022X.2020.1858100&partnerID=40&md5=af378028cae5fa767c7db739d9b60cf6

Files